Source-grounded facts extracted from CHINA PHARMA HOLDINGS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CHINA PHARMA HOLDINGS, INC. entered into Technology Transfer Agreement with Xiaoyan Zhang valued at $6.93 million (effective 2026-02-26).
“On February 26, 2026 (the “Signing Date”), Hainan Helpson Medical & Biotechnology Co., Ltd (“ Helpson ”), a wholly owned subsidiary of China Pharma Holdings, Inc. (the “ Company ”), entered into a Technology Transfer Agreement (the “ Agreement ”) with Xiaoyan Zhang (the “ Transferor ”). The Transferor owns an invention patent of an Prinsepia Utilis Esterol Sublingual Tablets and Method for Its Preparation (the “ Invention Patent ”). Pursuant to the Agreement, the Transferor will transfer the ownership of the Invention Patent to Helpson. The Transferor or its designated third party shall provide relevant technical services, which include but are not limited to product research and development, writing of registration materials, registration application and other technical services. The transfer price as contemplated by the Agreement is $6.93 million, which will be paid in the form of common stock of the Company, par value $0.001 per share, at $0.55 per share.”
Material Agreements
CHINA PHARMA HOLDINGS, INC. entered into Technology Transfer Agreement with Xiaoyun Chen valued at $8.82 million in common stock at $0.70 per share (effective 2026-02-05).
“On February 5, 2026 (the "Signing Date"), Hainan Helpson Medical & Biotechnology Co., Ltd (" Helpson "), a wholly owned subsidiary of China Pharma Holdings, Inc. (the " Company "), entered into a Technology Transfer Agreement (the " Agreement ") with Xiaoyun Chen (the " Transferor ").”
Auditor Changes
CHINA PHARMA HOLDINGS, INC. engaged Enrome LLP as its auditor.
“udit committee approved the engagement of Enrome LLP (“ Enrome ”) as the Company’s new independent registered public accounting firm.”
Auditor Changes
CHINA PHARMA HOLDINGS, INC. dismissed B F Borgers CPA PC as its auditor.
“F Borgers CPA PC (“ Borgers” ), denying its privilege of appearing or practicing before the SEC as an accountant. As a result of the Order, Borgers may not participate in or perform the audit or review of financial information included in the SEC filings, issue audit reports included in the SEC filings, provide consents with respect to audit reports, or otherwise appear or practice before the SEC. On May 7, 2024, China Pharma Holdings, Inc. (the “ Company ”), a corporation incorporated under the laws of the State of Nevada, terminated the engagement with Borgers serving as the Company’s independent registered public accounting firm. The termination of the engagement with Borgers was approved by the Company’s audit committee.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.